Pregnancy is a state of vasodilation mediated by nitric oxide (NO). This vasodilation is impaired in women with preeclampsia, and an alteration in the L-arginine-NO pathway may be a causal factor. The production of NO and arginase activity were investigated in plasma and human umbilical vein endothelial cells (HUVECs) from women with preeclampsia, which were associated with arginase II, eNOS, caveolin, angiotensin 1 and 2 receptor expression (AT 1 R and AT 2 R, respectively). The effect of ( À )-epicatechin on arginase activity and production of anion superoxide in HUVEC also were investigated. Healthy volunteer non-pregnant (HV), normal pregnant (NP) and preeclamptic (PE) women were recruited for this study. Higher values of nitrite/nitrate (NO 2 /NO 3 ) were detected in the plasma from PE women as opposed to HV and NP. Lower arginase activity in PE versus HV or NP women was observed. HUVECs from PE women showed lower values of NO 2 /NO 3 , higher activity of arginase and higher expression of AT 1 R and AT 2 R than HUVECS from NP women. Interestingly, arginase activity was associated with AT 2 R stimulation; indeed this activity and the high NADPH (nicotinamide adenine dinucleotide phosphate) oxidase activity in HUVECs from PE women can uncouple the production or inactivation of NO. However, we demonstrated that ( À )-epicatechin could lead to a decrease in the activity of both enzymes.
INTRODUCTION
Normal pregnancy induces a state of vasodilation partially mediated by the endothelium-derived vasodilator, nitric oxide (NO), 1 which reduces vascular resistance to adapt to the increased plasma volume that occurs in the pregnancy. This adaptation during pregnancy may be impaired in women with preeclampsia, thus leading to hypertension (systolic blood pressure X140 mm Hg or diastolic blood pressureX90 mm Hg) and proteinuria (X300 mg per 24 h), which are the characteristics of this syndrome. 2 It has been controversial whether endothelial dysfunction, such as a decrease in the production or inactivation of NO, could be a causal factor of the hypertension observed in preeclamptic (PE) women. 3 Several studies have shown that the production and bioactivity of NO has a key role in the hemodynamic adaptations of pregnancy. 4 NO is synthesized from the amino acid L-arginine by a family of enzymes, referred to as NO synthases (NOS). Regulation of NO production has been observed in endothelial cells by arginase, an enzyme that competes with NOS for an L-arginine substrate. 5 Arginase is a hydrolytic enzyme responsible for the conversion of L-arginine to urea and L-ornithine. 6 Two isoforms of arginase have been detected: arginase I (cytosolic), which is mainly expressed in the liver as a part of the urea cycle, and arginase II (mitochondrial), which is expressed in extrahepatic tissues, particularly in the kidney.
In the vasculature, arginase I is expressed both in vascular smooth muscle cells and in the endothelium, 7 while arginase II is highly expressed in the endothelium. 8 Several studies have associated elevated arginase activity with systemic hypertension. On the other hand, the inhibition of arginase improves vascular function in adult hypertensive rats, as well as in spontaneously hypertensive rats. 5, 9 Interestingly, arginase II expression has been shown to be increased in the placenta of women with preeclampsia, and its role in endothelial damage has been studied. 10, 11 These studies suggest a central role of arginase in diseases of vascular dysfunction, such as preeclampsia, in which impairment of the L-arginine-NO pathway could determine the production and bioavailability of NO.
The role of superoxide has been increasingly recognized because its generation leads to oxidative stress. Deleterious effects of this radical, including initiation of lipid peroxidation, oxidative damage to biomolecules and cellular dysfunction, are proposed to initiate maternal vascular endothelial dysfunction. Several reports have demonstrated that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is highly expressed in women with preeclampsia. 12, 13 Indeed, potential stimuli for the activation of NADPH oxidase in preeclampsia have been reported, including fetoplacental vascular shear stress, elevation of maternal plasma cytokine concentrations, 14 enhanced angiotensin 2 (AT 2 ) sensitivity, and a high concentration of an ImmunoglobulinG autoantibody that binds to the AT 1 receptor (AT 1 R-AA). 15 In this study, we investigated whether the production of NO and arginase activity in plasma from PE women could be reflecting the impairment of the L-arginine-NO pathway in this pathology. Additionally, we evaluated arginase activity in human umbilical vein endothelial cells (HUVECs) and its association with other proteins, such as caveolin, AT 1 R and AT 2 R. Finally, we evaluated the effect of ( À )-epicatechin as a possible modulator of the L-arginine-NO pathway and the production of anion superoxide in HUVECs from PE women.
MATERIALS AND METHODS

Subjects
Healthy volunteer non-pregnant (HV; n ¼ 14), normal pregnant (NP; n ¼ 24), and PE women (n ¼ 22) were recruited for this study at the Juarez Hospital of Mexico, Mexico, DF, Mexico. The Ethics and Research Committee from the School of Medicine of the National Polytechnic and Juarez Hospital of Mexico approved the protocol of this study; written informed consent was obtained from all patients, and the studies were conducted in accordance with the ethical principles delineated in the Declaration of Helsinki of 1975, revised in 1983. Finally, it was consistent with Good Clinical Practice Guidelines.
Measurement of arginase activity A sample of blood was obtained from the antecubital vein of the arm to obtain plasma and to determine arginase activity. Plasma was diluted five times to 100 ml (final volume) with a buffer containing 25 mM Tris-HCl and 5 mM MnCl 2 (pH 7.4). Arginase was then activated by heating the dilution to 56 1C for 10 min. L-Arginine hydrolysis was conducted by incubating the dilution with 100 ml of 0.5 M L-arginine (pH 9.7) at 37 1C for 60 min. The reaction was stopped with 400 ml of an acidic mixture (H 2 SO 4 , H 3 PO 4 and H 2 O; 1:3:7 v/v). Then, urea was measured at 545 nm after the addition of 25 ml of 9% a-isonitrosopropiophenone (dissolved in 100% ethanol); this solution was heated to 100 1C for 45 min to quantify arginase activity. 16 To determine the arginase activity in HUVECs, the cells were lysed with 0.5 ml of 25 mM Tris-HCl, 0.1% Triton X-100, and 5 mM PMSF. The lysate was centrifuged at 12 000 r.p.m. for 30 min at 4 1C, and the precipitate was eliminated. Twenty-five microliters of lysate were added to 25 ml of buffer (25 mM Tris-HCl and 5 mM MnCl 2 (pH 7.4)); then, arginase was activated by heating at 56 1C for 10 min, and its activity was assayed as mentioned above. Arginase activity in the presence of ( À )-epicatechin was assayed in the same way using 1 and 5 mM of flavanol for each experiment, respectively.
NO measurement
To measure NO in the plasma and HUVECs, Cayman's nitrate/ nitrite (NO 3 /NO 2 ) colorimetric assay kit was used (Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacturer's instructions.
HUVEC isolation and treatment
Cell culture studies were performed using HUVECs from NP and PE women. HUVECs were isolated from umbilical cords according to a previously described procedure. 17 Cells were grown on dishes in M199 with 1% endothelial cell growth supplement, heparin and 15% fetal bovine serum. They were used for experiments at passages 3-5.
The effect of AT 2 on arginase activity in HUVECs was assayed by plating 8 Â 10 6 cells and treating them with AT 2 (0.01 mM) for different amounts of time: 5, 10 and 15 min. Arginase activity was measured in cell lysates, as described above. When the cells were treated with AT 2 in the presence of inhibitors (1 mM Losartan, an AT 1 receptor blocker, and 1 mM PD123319, an AT 2 receptor blocker) (Sigma Aldrich, St Louis, MO, USA), blockers were added 2 h before the addition of AT 2 .
Protein expression
To determine the expression of eNOS, ARG II, AT 1 R, AT 2 R, Caveolin-1 and GADPH in HUVECs from NP and PE women, western blot assays were performed, employing specific antibodies against each of these proteins (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at specific final dilutions. After incubation with primary antibodies, the membranes were incubated with either a secondary goat anti-mouse peroxidase-labeled antibody or a secondary goat anti-rabbit peroxidase-labeled antibody diluted in the blocking solution for 1 h at room temperature. The blots were washed, and the proteins were developed with diaminobenzidine solution. The blots were incubated with a monoclonal antibody against GADPH as a loading control. Images from the blots were digitally acquired with a BioDoc-It System, and densitometry analysis was performed in Lab Works 4.0 image acquisition and analysis software (UVP, Inc. Upland, CA, USA). Densitometry results of the different proteins were normalized with respect to their GAPDH control, and the data were expressed in normalized arbitrary optical density units.
Measurement of NADPH oxidase activity with electroparamagnetic resonance (EPR)
For EPR studies, 8 Â 10 6 HUVECs from NP and PE women were plated in 100-cm plates until they reached 90% confluence. Cells were collected by scraping and centrifugation, and then the pellet was resuspended in 200 ml of lysis buffer (Tris-HCl 25 mM pH 7.4, protease inhibitors (Roche Diagnostics. Indianapolis, IN, USA)). HUVECs were homogenized, and 30 mg of protein from the lysate was added to the reaction buffer (100 mM NADPH, 100 mM NADH, 10 mM porbol). The spin probe CMH (1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine) was used at a final concentration of 5 mM for 30 min at 37 1C. Subsequently, the mix reaction was loaded into 50 ml glass capillaries and placed into a temperature-and gas-controlled EPR cavity for 10 min. Control samples, in the absence of a cell sample, were conducted to determine the auto-oxidation of the spin probe under our experimental conditions, and the control signal intensity values were subtracted from the experimental signal intensity values. Oxidation of CMH was analyzed using an e-scan Bio-Spin Bruker spectrometer (Bruker Mexicana, S.A. de C.V. Mé xico D.F). The EPR instrument settings were as follows: field sweep, 60 G; microwave frequency, 9.737 GHz; microwave power, 17.393 mW; modulation amplitude, 1.55 G; conversion time, 10.240 ms; time constant, 40.960 ms; and receiver gain, 5.64e þ 001. When NADPH oxidase activity was performed in the presence of ( À )-epicatechin, flavanol was included in the mix reaction at a final concentration 1 or 5 mM, and the assay was performed as described above. NADPH oxidase activity was expressed as the area under the curve of each spectrum.
Statistical analysis Data are expressed as the mean±standard error (s.e.) or as s.d. Analysis of variance (ANOVA) combined with Bonferroni post-hoc tests were used to analyze the clinical characteristics of the study groups, NO 2 /NO 3 levels and arginase activity. Student's t-test was used to determine statistically significant differences in protein expression and areas under the curve of each ERP spectrum. P-valueso0.05 were considered to be statistically significant. All tests were performed using Prism 5 software (GraphPad, San Diego, CA, USA).
RESULTS
Study groups
Twenty-four NP, 22 PE and 14 HV women participated in this study. The clinical parameters of these subjects are included in Table 1 . As expected, the PE group had higher blood pressure and higher prevalence of proteinuria than the NP and HV groups (Po0.05).
NOS and arginase activity in plasma We investigated whether NO production and arginase activity in plasma from PE women could be indicators of this dysfunction. Higher values of NO 2 /NO 3 were detected in the plasma of PE women (0.31 ± 0.04 nmol per mg protein) in comparison with HV (0.24 ± 0.02 nmol per mg protein) and NP women (0.22±0.02 nmol per mg protein) (Figure 1a) . Additionally, lower arginase activity was observed in PE patients (0.31±0.03 nmol per mg protein per min) in comparison with HV (0.42 ± 0.04 nmol per mg protein per min) and NP women (0.45 ± 0.05 nmol per mg protein per min) (Figure 1b) . The data showed the existence of a higher synthesis of NO in PE women, which could be related to the lower arginase activity detected in these patients. As NO synthesis and arginase levels do not reflect endothelial dysfunction, we endeavored to analyze these enzymatic activities directly in endothelial cells. Endothelial cells were obtained from the umbilical cord of NP and PE women, and the activities of these enzymes were analyzed. The data showed a lower NO synthesis in endothelial cells from PE (0.5±0.16 nmol per mg protein) compared with NP women (1 ± 0.07 nmol per mg protein) (Figure 1c) , although higher activity of arginase was observed in endothelial cells from PE (82±11.83 nmol per mg protein permin) versus NP women (43±5.5 nmol permg protein per min) (Figure 1d) . Interestingly, the data obtained were inconsistent with observations made in the plasma, suggesting that an impaired L-arginine-NO pathway is only observed at the endothelial level.
We analyzed whether the effects observed were related to changes in eNOS and arginase II expression; interestingly, the western blot assay did not detect any changes in these enzymes (Figure 2a , to see a complete picture of these western blot, please refer additional data Supplementary Figures S1a, c and d) , indicating a change in arginase activity alone. This result suggests that arginase could be sequestering arginine, the first substrate in the NO synthesis pathway. As several proteins, such as caveolin, AT 1 R and AT 2 R, have been related to eNOS regulation in endothelial cells, we investigated whether changes in the expression of these proteins could be related to lower observed NO synthesis. A protein extract was obtained from endothelial cells from NP and PE women, and the expression of these proteins was analyzed. No change was detected for caveolin (Figure 2a ; additional data Supplementary Figure S1b) ; however, higher expressions of AT 1 R and AT 2 R were observed (Figures 2a and b , a complete picture of each western blot is available as additional data Supplementary Figures S1e-h ). These changes were also detected by immunofluorescence (data not shown). Interestingly, these results were in agreement with previous evidence where angiotensin dysregulation was related to high blood pressure and endothelial dysfunction.
Effect of AT 2 on arginase activity in HUVECs from NP and PE women As the endothelial damage observed in PE women was related to high arginase activity and elevated levels of angiotensin receptors, we sought to establish the relationship between ATR and arginase activity. HUVECs from NP and PE women were stimulated with Figure 1 . Levels of NO 3 /NO 2 and arginase activity in HV, NP and PE women. High levels of NO 3 /NO 2 and low arginase activity were observed in plasma from PE women (a, b, respectively). In contrast, low levels of NO 3 /NO 2 and high arginase activity were observed in endothelial cell from PE women (c, d, respectively). Data are expressed as mean±s.d., analyzed by ANOVA combined with Bonferroni post-hoc tests (Pp0.05).
angiotensin at different times, and arginase activity was evaluated (see Materials and methods). Figure 3a shows that arginase activity was increased in both NP and PE HUVECs; however, higher arginase activity could be induced in HUVECs from PE women at 5 min compared with NP women. Indeed, this activation was followed by increased Akt phosphorylation (Figure 3b , a complete picture of p-Akt western blot is available as additional data Supplementary Figure S2) . Furthermore, when we used specific inhibitors of the AT 2 R (PD123319), the increase in arginase activity was prevented, demonstrating the important role of this receptor in the arginase activation in HUVECs (Figure 3c ).
NADPH oxidase activity in HUVECs from NP and PE women The induction of arginase activity by AT 2 suggested an inhibition in NO synthesis by possible substrate competition between arginase and eNOS ( Figure 3d ). We also analyzed NADPH oxidase activity, the major source of superoxide in endothelial cells, given that NO and the superoxide anion (O 2 À ) can form peroxynitrite to inactivate NO (Figure 3d) . Interestingly, when the activity of this enzyme was analyzed by EPR, we found 4.5 times higher activity of this enzyme in HUVECs from PE (6.337 Â 10 7 arbitrary units) as opposed to NP (1.38 Â 10 7 arbitrary units) ( Figure 4a ). As a relationship between AT 2 R activation by AT 2 and an increase in NADPH oxidase activity has been proposed, we analyzed the activity of this enzyme when HUVECs were stimulated with AT 2 (5 min) and when higher arginase activity was observed. No increase in NADPH oxidase activity was observed; a decrease was detected, suggesting that AT 2 could have a negative regulator effect on NADPH oxidase activity after a short period of stimulation (data not shown).
( À )-Epicatechin decreases arginase and NADPH oxidase activity in HUVECs from PE women Considering that our data suggested the presence of two NO inactivation mechanisms (Figure 3d ), we investigated whether the vasodilatory effect reported with ( À )-epicatechin could be associated with arginase or NADPH oxidase activity regulation at the endothelial level. To achieve this, HUVECs from PE women were grown to 90% confluence, incubated with ( À )-epicatechin (1 or 5 mM) for 15 min, and then NADPH oxidase activity was determined by EPR. The results obtained indicated that ( À )-epicatechin decreased NADPH oxidase activity (Figure 4a ). Additionally, when arginase activity was analyzed under these conditions, a decrease in its activity was also observed (data not shown). Because of an increase in arginase activity induced by AT 2 (Figure 3c ), we investigated whether this induction could be prevented by ( À )-epicatechin. The results obtained showed that ( À )-epicatechin (1 or 5 mM) inhibited arginase activity even in the presence of AT 2 (Figure 4c ).
DISCUSSION
The main characteristics of preeclampsia are high blood pressure, proteinuria and edema in pregnancy, and it is one of the leading causes of maternal mortality. These characteristics of the disease reflect important clues on widespread endothelial dysfunction. In this study, we evaluated the L-arginine-NO pathway in the plasma of women with preeclampsia and found no association with endothelial dysfunction. However, when the L-arginine-NO pathway was evaluated in HUVECs from women with preeclampsia, we observed impairment in this pathway, in fact, similar results have been reported by other groups and this paradox has been clarified proposing the existence of an independency between NO 2 /NO 3 levels and the cyclic guanosine monophosphate (cGMP) concentration. Indeed, the evidences that show higher NO 2 /NO 3 levels and lower cGMP concentration in different biologic samples from women with preeclampsia support this possibility. [18] [19] [20] Interestingly, we also showed that these cells had increased expression of AT 1 and AT 2 receptors, suggesting that the expression and stimulation of the AT 2 receptor is an important factor in the higher arginase II activity observed in these cells. Although the basal level of arginase activity detected was three times higher in HUVECs from women with preeclampsia, the activity increase observed after stimulation with AT 2 also increased proportionately.
Currently, there is evidence that indicates the physiological importance of arginase during pregnancy. Specifically, increased arginase expression has been reported in normal pregnancies in different species. However, increased arginase activity in the vasculature of women with preeclampsia can impair the L-arginine-NO pathway contributing to endothelial dysfunction. [21] [22] [23] Additionally, we observed enhanced NADPH oxidase activity in HUVECs from women with preeclampsia ; interestingly, a stimulation of this enzyme by the activation of AT 2 R has been reported; these observations suggest a possible relationship between the high expression of this receptor and NADPH oxidase activity, which could be inducing the formation of high O 2 À concentration, and as a consequence a degradation or inactivation of NO, due to the high reactivity between NO and O 2 À to form peroxinitrite. [24] [25] [26] [27] Interestingly, we showed that ( À )-epicatechin, a reactive oxygen species (ROS) scavenger, significantly reduced arginase activity in HUVECs from PE women when the cells were stimulated with AT 2 . In addition, NADPH activity was also reduced by flavanol, suggesting that the inhibition of both enzymes by this molecule could increase NO synthesis, decrease superoxide levels and consequently improve the bioavailability of NO. These results suggest that ( À )-epicatechin supplementation could result in beneficial effects during preeclampsia because of its ability to enhance NO formation and bioavailability.
Several studies have linked arginase activity alteration with vascular disease and with high expression levels of AT 2 , 5,28,29 a component of the renin-angiotensin system, that interacts with the AT 1 and AT 2 receptors. In our study, the prevention of AT 2 -induced elevation of arginase activity by the AT 2 blocker PD-123319 indicated that AT 2 induces arginase activity through the AT 2 receptor. Several reports have shown that most of the vasoconstriction effects of AT 2 are mediated by the AT 1 receptor, 30, 31 whereas the AT 2 R has been shown to oppose AT 1 's effects by vasodilatation and natriuresis. 32 Our study revealed an important role of AT 2 in the impairment of the L-arginine-NO pathway in the endothelial cells of PE women. We interpreted these results to suggest that increased AT 2 -mediated arginase activity can induce decreased synthesis and bioavailability of NO, which contributes to enhanced vasoconstriction.
Interestingly, the ratio of AT 1 to AT 2 receptor increase has been reported as a net effect of pregnancy. However, the evidence that demonstrates the association of a higher proportion of AT 2 receptors with the development of preeclampsia/eclampsia supports ours observations. 32 It is important to mention that several studies suggest that preeclampsia is a placental pathology owing to its sudden resolution after placental birth. Nevertheless, our study shows that the higher arginase and NADPH activity observed in endothelial cells from PE women could be contributing to vasoconstriction (Figure 3d ). These observations are supported by previous reports in which arginase and NADPH oxidase activity are associated with a diminished production of NO. 33 Lastly, the study in preeclampsia has focused on the prediction of the disease to diminish its mortality and morbidity. Herein, we showed that the deleterious effects molecules related to endothelial damage do not reflect their plasma levels. Finally, we showed that the exposure of endothelial cells from PE women to ( À )-epicatechin resulted in decreased arginase and NADPH oxidase activity, supporting the potential of this molecule in the development of novel disease treatments.
What is known about this topic
Several studies have suggested the presence of endothelial dysfunction as a causal factor of the hypertension in preeclampsia. 3 An increase in arginase activity has been shown in the placenta of women with preeclampsia, and its role in endothelial damage has been studied. 10, 11 The role of AT1R, AT2R and superoxide anion has been increasingly recognized in preeclampsia because of its deleterious effects to initiate maternal vascular endothelial dysfunction.
12,13
What this study adds This study shows that an evaluation of L-arginine-NO pathway in plasma from women with preeclampsia does not reflect the presence of an endothelial dysfunction. However, higher arginase activity and lower production of NO in HUVECs from women with preeclampsia corroborated the presence of an endothelial dysfunction, which were in agreement with high expression of AT 1 R, AT 2 R and high production of superoxide anion. Finally, this study shows that high arginase activity is generated by an activation of AT 2 R, which can be prevented by ( À )-epicatechin, a molecule that also decreases the production of superoxide anion.
